These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 27399114)

  • 1. A case report: The efficacy of pirfenidone in a Chinese patient with progressive systemic sclerosis-associated interstitial lung disease: A CARE-compliant article.
    Huang H; Feng RE; Li S; Xu K; Bi YL; Xu ZJ
    Medicine (Baltimore); 2016 Jul; 95(27):e4113. PubMed ID: 27399114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
    Khanna D; Albera C; Fischer A; Khalidi N; Raghu G; Chung L; Chen D; Schiopu E; Tagliaferri M; Seibold JR; Gorina E
    J Rheumatol; 2016 Sep; 43(9):1672-9. PubMed ID: 27370878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-fibrotic effects of pirfenidone by interference with the hedgehog signalling pathway in patients with systemic sclerosis-associated interstitial lung disease.
    Xiao H; Zhang GF; Liao XP; Li XJ; Zhang J; Lin H; Chen Z; Zhang X
    Int J Rheum Dis; 2018 Feb; 21(2):477-486. PubMed ID: 29316328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II.
    Tashkin DP; Volkmann ER; Tseng CH; Roth MD; Khanna D; Furst DE; Clements PJ; Theodore A; Kafaja S; Kim GH; Goldin J; Ariolla E; Elashoff RM
    Chest; 2017 Apr; 151(4):813-820. PubMed ID: 28012804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Design and Rationale of the Trail1 Trial: A Randomized Double-Blind Phase 2 Clinical Trial of Pirfenidone in Rheumatoid Arthritis-Associated Interstitial Lung Disease.
    Solomon JJ; Danoff SK; Goldberg HJ; Woodhead F; Kolb M; Chambers DC; DiFranco D; Spino C; Haynes-Harp S; Hurwitz S; Peters EB; Dellaripa PF; Rosas IO;
    Adv Ther; 2019 Nov; 36(11):3279-3287. PubMed ID: 31515704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
    van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
    Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Report: Successful Treatment of Refractory Interstitial Lung Disease With Cyclosporine A and Pirfenidone in a Child With SLE.
    Deng L; Chen Y; Hu X; Zhou J; Zhang Y
    Front Immunol; 2021; 12():708463. PubMed ID: 34671344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.
    Adler S; Huscher D; Siegert E; Allanore Y; Czirják L; DelGaldo F; Denton CP; Distler O; Frerix M; Matucci-Cerinic M; Mueller-Ladner U; Tarner IH; Valentini G; Walker UA; Villiger PM; Riemekasten G;
    Arthritis Res Ther; 2018 Jan; 20(1):17. PubMed ID: 29382380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antifibrotic therapy - new approvals for non-IPF interstitial lung diseases].
    Markart P; Drakopanagiotakis F; Wygrecka M
    Dtsch Med Wochenschr; 2021 Feb; 146(3):181-184. PubMed ID: 33513653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
    Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viewpoint: a multidisciplinary approach to the assessment of patients with systemic sclerosis-associated interstitial lung disease.
    Chatterjee S; Perelas A; Yadav R; Kirby DF; Singh A
    Clin Rheumatol; 2023 Mar; 42(3):653-661. PubMed ID: 36271064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease.
    Khanna D; Tashkin DP; Denton CP; Renzoni EA; Desai SR; Varga J
    Am J Respir Crit Care Med; 2020 Mar; 201(6):650-660. PubMed ID: 31841044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial.
    Acharya N; Sharma SK; Mishra D; Dhooria S; Dhir V; Jain S
    Rheumatol Int; 2020 May; 40(5):703-710. PubMed ID: 32239322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Chinese herb Tripterygium wilfordii Hook F for the treatment of systemic sclerosis-associated interstitial lung disease: data from a Chinese EUSTAR Center.
    Yang L; Wang Q; Hou Y; Zhao J; Li M; Xu D; Zeng X
    Clin Rheumatol; 2020 Mar; 39(3):813-821. PubMed ID: 31713733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Interstitial lung disease in systemic sclerosis].
    Mouthon L; Berezné A; Brauner M; Kambouchner M; Guillevin L; Valeyre D
    Presse Med; 2006 Dec; 35(12 Pt 2):1943-51. PubMed ID: 17159721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
    Ueda T; Sakagami T; Kikuchi T; Takada T
    Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interstitial lung disease in systemic sclerosis.
    Bussone G; Mouthon L
    Autoimmun Rev; 2011 Mar; 10(5):248-55. PubMed ID: 20863911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases.
    Takahashi T; Asano Y; Amiya E; Hatano M; Tamaki Z; Ozeki A; Watanabe A; Kawarasaki S; Nakao T; Taniguchi T; Ichimura Y; Toyama T; Watanabe M; Hirata Y; Nagai R; Sato S
    Mod Rheumatol; 2012 Aug; 22(4):598-601. PubMed ID: 22015621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Desquamative interstitial pneumonia as the initial manifestation of systemic sclerosis.
    Swartz JS; Chatterjee S; Parambil JG
    J Clin Rheumatol; 2010 Sep; 16(6):284-6. PubMed ID: 20808169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.